Encapsulating security : pharmaceutical defenses against biological danger -- Discovering a virus's achilles heel : flu fighting at molecular scale -- The pill always wins: Gilead Sciences, Roche and the birth of Tamiflu -- What a difference a day makes : the margin call for regulatory agencies -- Virtual blockbuster : bird flu and the pandemic of preparedness planning -- In the eye of the storm : global access, generics and intellectual property -- 'Ode to Tamiflu' : side effects, teenage 'suicides' and corporate liabilities -- Data backlash : Roche and Cochrane square up over clinical trial data -- 'To boldly go ... ' : pharmaceutical enterprises and global health security -- Epilogue : pharmaceuticals, security and molecular life

Providing an immediate, contemporary example of a region networking its response to disease outbreak events, this insightful book will appeal to global health governance scholars, students, and practitioners.

Updated with bonus material, including a new foreword and afterword with new research, this New York Times bestseller is essential reading for a time when mental health is constantly in the news. In this astonishing and startling book, award-winning science and history writer Robert Whitaker investigates a medical mystery: Why has the number of disabled mentally ill in the United States tripled over the past two decades? Interwoven with Whitaker’s groundbreaking analysis of the merits of psychiatric medications are the personal stories of children and adults swept up in this epidemic. As Anatomy of an Epidemic reveals, other societies have begun to alter their use of psychiatric medications and are now reporting much improved outcomes . . . so why can’t such change happen here in the United States? Why have the results from these long-term studies—all of which point to the same startling conclusion—been kept from the public? Our nation has been hit by an epidemic of disabling mental illness, and yet, as Anatomy of an Epidemic reveals, the medical blueprints for curbing that epidemic have already been drawn up. Praise for Anatomy of an Epidemic “The timing of Robert Whitaker’s Anatomy of an Epidemic, a comprehensive and highly readable history of psychiatry in the United States, couldn’t be better.”—Salon “Anatomy of an Epidemic offers some answers, charting controversial ground with mystery-novel pacing.”—TIME “Lucid, pointed and important, Anatomy of an Epidemic should be required reading for anyone considering extended use of psychiatric medicine. Whitaker is at the height of his powers.” —Greg Critser, author of Generation Rx

̀This is an excellent book which provides an authoritative introduction to the subject coupled with challenging and original new line of thinking about the problem of securing global health.' Colin McInnes, Aberystwyth University --

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

Over the past few decades a number of emerging infectious diseases (EIDs) have disrupted societies throughout the world, including HIV, Ebola, H5N1 (or ‘‘avian flu’’) and SARS, and of course the coronavirus disease (COVID-19) which spread worldwide to become a global pandemic. As well as EIDs, countries and regions also contend with endemic diseases, such as malaria. There are many factors that have contributed to the rise in, and spread of, EIDs and other diseases, including overpopulation, rapid urbanization, environmental degradation, and antibiotic resistance. Political and cultural responses to disease can greatly affect their spread. The global community needs to defend itself against disease threats: one weak link is enough to start a chain reaction that results in a global pandemic such as COVID-19. Some states take a nationalistic approach towards combating disease; however, international cooperation and meaningful ‘‘viral sovereignty’’—empowering countries to create effective health institutions and surveillance systems in order to contain disease—must be considered. This volume, with a focus on Southeast Asia, Africa and North America, considers the intersection between disease, politics, science, and culture in the global battle against pandemics, making use of case studies and interviews to examine the ways in which governments and regions handle outbreaks and pandemics.

Touching on a range of disease, from leishmaniasis, schistosomiasis, and Middle East Respiratory Syndrome (MERS) to COVID-19, Preventing the Next Pandemic has always been a timely goal, but it will be even more important in a COVID and post-COVID world.